These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28495644)

  • 1. Improving core outcome set development: qualitative interviews with developers provided pointers to inform guidance.
    Gargon E; Williamson PR; Young B
    J Clin Epidemiol; 2017 Jun; 86():140-152. PubMed ID: 28495644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of qualitative methods to inform Delphi surveys in core outcome set development.
    Keeley T; Williamson P; Callery P; Jones LL; Mathers J; Jones J; Young B; Calvert M
    Trials; 2016 May; 17(1):230. PubMed ID: 27142835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Participating in core outcome set development via Delphi surveys: qualitative interviews provide pointers to inform guidance.
    Biggane AM; Williamson PR; Ravaud P; Young B
    BMJ Open; 2019 Nov; 9(11):e032338. PubMed ID: 31727660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey indicated that core outcome set development is increasingly including patients, being conducted internationally and using Delphi surveys.
    Biggane AM; Brading L; Ravaud P; Young B; Williamson PR
    Trials; 2018 Feb; 19(1):113. PubMed ID: 29454368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodology in core outcome set (COS) development: the impact of patient interviews and using a 5-point versus a 9-point Delphi rating scale on core outcome selection in a COS development study.
    Remus A; Smith V; Wuytack F
    BMC Med Res Methodol; 2021 Jan; 21(1):10. PubMed ID: 33413129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ensuring young voices are heard in core outcome set development: international workshops with 70 children and young people.
    Sherratt FC; Bagley H; Stones SR; Preston J; Hall NJ; Gorst SL; Young B
    Res Involv Engagem; 2020; 6():19. PubMed ID: 32391170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient participation impacts outcome domain selection in core outcome sets for research: an updated systematic review.
    Dodd S; Gorst SL; Young A; Lucas SW; Williamson PR
    J Clin Epidemiol; 2023 Jun; 158():127-133. PubMed ID: 37054902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol for the development of a core outcome set for pelvic girdle pain, including methods for measuring the outcomes: the PGP-COS study.
    Wuytack F; Gutke A; Stuge B; Mørkved S; Olsson C; Robinson HS; Vøllestad NK; Öberg B; Wikmar LN; Mena JJS; Smith V
    BMC Med Res Methodol; 2018 Dec; 18(1):158. PubMed ID: 30509216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Representation of published core outcome sets in practice guidelines.
    Rhodes S; Dodd S; Deckert S; Vasanthan L; Qiu R; Rohde JF; Florez ID; Schmitt J; Nieuwlaat R; Kirkham J; Williamson PR
    J Clin Epidemiol; 2024 May; 169():111311. PubMed ID: 38423401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods used in the selection of instruments for outcomes included in core outcome sets have improved since the publication of the COSMIN/COMET guideline.
    Gorst SL; Prinsen CAC; Salcher-Konrad M; Matvienko-Sikar K; Williamson PR; Terwee CB
    J Clin Epidemiol; 2020 Sep; 125():64-75. PubMed ID: 32470621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core Outcome Set-STAndards for Reporting: The COS-STAR Statement.
    Kirkham JJ; Gorst S; Altman DG; Blazeby JM; Clarke M; Devane D; Gargon E; Moher D; Schmitt J; Tugwell P; Tunis S; Williamson PR
    PLoS Med; 2016 Oct; 13(10):e1002148. PubMed ID: 27755541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.
    Ma C; Panaccione R; Fedorak RN; Parker CE; Khanna R; Levesque BG; Sandborn WJ; Feagan BG; Jairath V
    BMJ Open; 2017 Jun; 7(6):e016146. PubMed ID: 28601837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion of harm outcomes in core outcome sets requires careful consideration.
    Tay J; Robinson C; Blazeby J; Loke Y; Lowery A; Alkhaffaf B; Kirkham JJ
    J Clin Epidemiol; 2024 Oct; 174():111474. PubMed ID: 39038744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance.
    Aiyegbusi OL; di Ruffano LF; Retzer A; Newsome PN; Buckley CD; Calvert MJ
    Trials; 2022 Jan; 23(1):42. PubMed ID: 35033186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-depth qualitative interviews identified barriers and facilitators that influenced chief investigators' use of core outcome sets in randomised controlled trials.
    Hughes KL; Williamson PR; Young B
    J Clin Epidemiol; 2022 Apr; 144():111-120. PubMed ID: 34896233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for conducting international Delphi surveys to optimise global participation in core outcome set development: a case study in gastric cancer informed by a comprehensive literature review.
    Alkhaffaf B; Blazeby JM; Metryka A; Glenny AM; Adeyeye A; Costa PM; Del Val ID; Gisbertz SS; Guner A; Law S; Lee HJ; Li Z; Nakada K; Nuñez RMR; Reim D; Reynolds JV; Vorwald P; Zanotti D; Allum W; Chaudry MA; Griffiths E; Williamson PR; Bruce IA;
    Trials; 2021 Jun; 22(1):410. PubMed ID: 34154641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding successful development of complex health and healthcare interventions and its drivers from the perspective of developers and wider stakeholders: an international qualitative interview study.
    Turner KM; Rousseau N; Croot L; Duncan E; Yardley L; O'Cathain A; Hoddinott P
    BMJ Open; 2019 May; 9(5):e028756. PubMed ID: 31152042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement was needed in the standards of development for cancer core outcome sets.
    Gargon E; Williamson PR; Blazeby JM; Kirkham JJ
    J Clin Epidemiol; 2019 Aug; 112():36-44. PubMed ID: 31009657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cauda Equina Syndrome Core Outcome Set (CESCOS): An international patient and healthcare professional consensus for research studies.
    Srikandarajah N; Noble A; Clark S; Wilby M; Freeman BJC; Fehlings MG; Williamson PR; Marson T
    PLoS One; 2020; 15(1):e0225907. PubMed ID: 31923259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.